*ST赛隆：子公司获得右兰索拉唑化学原料药上市申请批准通知书

Core Viewpoint - *ST Sailong (002898) has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Rabeprazole, which is indicated for the treatment of bleeding gastric and duodenal ulcers when oral therapy is not suitable [1] Group 1 - The company's wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., has obtained the approval notice for Rabeprazole injection [1] - Rabeprazole injection is specifically used for treating gastric ulcers and duodenal ulcers associated with bleeding [1]